III期-话题@MedSci

#III期#

681篇内容 | 2804人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594727, encodeId=740d1594e27dd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, objectType=article, longId=191476, objectId=71041914e630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71041914e630, replyNumber=0, likeNumber=80, createdTime=2020-04-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71041914e630, moduleTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71041914e630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594726, encodeId=d0011594e26b8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=鼻息肉靶向治疗药物研究成功：IL-5单抗mepolizumab的III期研究效果显著（SYNAPSE研究）, objectType=article, longId=191428, objectId=b8ab191428cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ab191428cc, replyNumber=0, likeNumber=88, createdTime=2020-04-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ab191428cc, moduleTitle=鼻息肉靶向治疗药物研究成功：IL-5单抗mepolizumab的III期研究效果显著（SYNAPSE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ab191428cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594725, encodeId=76d61594e256d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=达格列净III期DAPA-CKD研究因在慢性肾脏病患者中的压倒性疗效而计划提前终止, objectType=article, longId=191213, objectId=325f19121325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=325f19121325, replyNumber=0, likeNumber=84, createdTime=2020-04-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=325f19121325, moduleTitle=达格列净III期DAPA-CKD研究因在慢性肾脏病患者中的压倒性疗效而计划提前终止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=325f19121325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594724, encodeId=d3b21594e24fb, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=14, createdTime=2020-03-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594723, encodeId=27451594e231d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, objectType=article, longId=190693, objectId=7c61190693ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c61190693ac, replyNumber=0, likeNumber=14, createdTime=2020-03-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c61190693ac, moduleTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c61190693ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594722, encodeId=67901594e2207, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=20价肺炎球菌结合疫苗（20vPnC）的III期临床结果, objectType=article, longId=190431, objectId=604619043165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=604619043165, replyNumber=0, likeNumber=47, createdTime=2020-03-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=604619043165, moduleTitle=20价肺炎球菌结合疫苗（20vPnC）的III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=604619043165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594721, encodeId=c2b31594e213e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果, objectType=article, longId=190430, objectId=bffb1904303e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bffb1904303e, replyNumber=0, likeNumber=63, createdTime=2020-03-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bffb1904303e, moduleTitle=III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bffb1904303e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594720, encodeId=c8091594e20d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, objectType=article, longId=190422, objectId=cfc8190422fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc8190422fa, replyNumber=0, likeNumber=75, createdTime=2020-03-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc8190422fa, moduleTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc8190422fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594719, encodeId=a8181594e1913, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=19, createdTime=2020-03-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594718, encodeId=41951594e18f9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , objectType=article, longId=189573, objectId=89671895e3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89671895e3b8, replyNumber=0, likeNumber=14, createdTime=2020-03-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89671895e3b8, moduleTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89671895e3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594717, encodeId=72871594e17bb, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=16, createdTime=2020-03-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594716, encodeId=6f901594e16fa, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, objectType=article, longId=189361, objectId=9e5418936139, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e5418936139, replyNumber=0, likeNumber=69, createdTime=2020-03-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e5418936139, moduleTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5418936139)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594715, encodeId=c4181594e15de, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%, objectType=article, longId=189360, objectId=4814189360cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4814189360cb, replyNumber=0, likeNumber=65, createdTime=2020-03-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4814189360cb, moduleTitle=喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4814189360cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594714, encodeId=73261594e1427, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, objectType=article, longId=188485, objectId=ddfc1884854b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddfc1884854b, replyNumber=0, likeNumber=20, createdTime=2020-02-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddfc1884854b, moduleTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddfc1884854b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594713, encodeId=72a21594e131a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=70, createdTime=2020-02-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594712, encodeId=a6641594e1200, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, objectType=article, longId=188050, objectId=0cde18805010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cde18805010, replyNumber=0, likeNumber=56, createdTime=2020-02-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cde18805010, moduleTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cde18805010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594711, encodeId=9e1d1594e118d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, objectType=article, longId=187677, objectId=e89218e67760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e89218e67760, replyNumber=0, likeNumber=12, createdTime=2020-02-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e89218e67760, moduleTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e89218e67760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594710, encodeId=9fbf1594e108c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, objectType=article, longId=187585, objectId=d55418e58511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55418e58511, replyNumber=0, likeNumber=57, createdTime=2020-02-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55418e58511, moduleTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d55418e58511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594709, encodeId=abba1594e096f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后, objectType=article, longId=187354, objectId=313c18e3543f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313c18e3543f, replyNumber=0, likeNumber=16, createdTime=2020-02-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313c18e3543f, moduleTitle=Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313c18e3543f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594708, encodeId=65011594e0831, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功, objectType=article, longId=187116, objectId=145b18e11654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=145b18e11654, replyNumber=0, likeNumber=80, createdTime=2020-02-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=145b18e11654, moduleTitle=口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=145b18e11654)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验

2020-04-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

鼻息肉靶向治疗药物研究成功：IL-5单抗mepolizumab的III期研究效果显著（SYNAPSE研究）

2020-04-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

达格列净III期DAPA-CKD研究因在慢性肾脏病患者中的压倒性疗效而计划提前终止

2020-04-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2020-03-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

2020-03-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

20价肺炎球菌结合疫苗（20vPnC）的III期临床结果

2020-03-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果

2020-03-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著

2020-03-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-03-16

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究

2020-03-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-03-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！

2020-03-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%

2020-03-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

2020-02-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-02-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

2020-02-16

智智灵药 (审核中...)

前往app查看评论内容

#III期#

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-02-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册

2020-02-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后

2020-02-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功

2020-02-03

科室
- - 订阅+
  - 更多科室
工具
服务